Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARETIMI58). ClinicalTrials.gov, NCT01730534, 2018.
A study to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease (Dapa-CKD). ClinicalTrials.gov, NCT03036150, 2017.
EMPA-KIDNEY (the study of heart and kidney protection with empagliflozin). ClinicalTrials.gov, NCT03594110, 2018.